Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer’s disease pathology

Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ 42 ) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ 42 /Aβ 40 and p-tau181/Aβ 42 ) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ 42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ 42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.

Authors

Institutions

Publication Details

Journal
Nature Aging
Published
2026-11-18
DOI
https://doi.org/10.1038/s43587-026-01259-z
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer’s disease pathology

Lyduine Eisa Collij, Nicholas James Ashton, Sebastian Palmqvist, Erik Stomrud et al.
8 links
Nature Aging
Dementia and Cognitive Impairment Research
article

Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer’s disease pathology

Lyduine Eisa Collij, Nicholas James Ashton, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Olof T. Strandberg, Ruben A Smith, Niklas Mattsson, Oskar Hansson, Gemma Salvadó, Henrik Zetterberg, Shorena Janelidze, Noëlle Warmenhoven, Michael Walter Weiner, Alzheimer’s Disease Neuroimaging Initiative, Alexa Pichet Binette
article en

Abstract

Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ 42 ) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ 42 /Aβ 40 and p-tau181/Aβ 42 ) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ 42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ 42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.

Nature Aging
University of Wisconsin–Madison (US), University of California, San Francisco (US), Lund University (SE), Sahlgrenska University Hospital (SE), Pasqual Maragall Foundation (ES), Amsterdam Neuroscience (NL), UK Dementia Research Institute (GB), Institut Universitaire de Gériatrie de Montréal (CA), Barcelonaβeta Brain Research Center (ES), Skåne University Hospital (SE), Banner Sun Health Research Institute (US), Hospital del Mar Research Institute (ES), Northern California Institute for Research and Education (US), Banner Alzheimer’s Institute (US), UCL Queen Square Institute of Neurology (GB), University College London (GB), Université de Montréal (CA), University of Gothenburg (SE), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
U.S. Department of Defense, Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, Biogen, University of Southern California, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, Cure Alzheimer's Fund, BioClinica, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, Australian Government, GHR Foundation, Lunds Universitet, Eisai, Vetenskapsrådet, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skånes universitetssjukhus, Servier, H. Lundbeck A/S, IXICO, Stiftelsen Bundy Academy, National Institutes of Health, Genentech, Parkinsonfonden, Canadian Institutes of Health Research, Janssen Alzheimer Immunotherapy Research And Development
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon